As urged by the AHA, the Health Resources and Services Administration today announced that it expects to publish online by April 1 drug ceiling prices under the 340B Drug Pricing Program. HRSA also notified stakeholders that the secure pricing component of the 340B Office of Pharmacy Affairs Information System will be open for the submission of manufacturer pricing data in the first quarter of 2019.

The Department of Health and Human Services yesterday issued a final rule making Jan. 1 the effective date of its final regulations on drug ceiling prices and civil monetary penalties for manufacturers under the 340B program. The AHA said it was pleased that, in response to its lawsuit, the “final rule ensures that the implementation of the long-delayed” 340B ceiling price and civil monetary penalties policies will be effective Jan. 1. 

The AHA, Association of American Medical Colleges, America's Essential Hospitals, 340B Health and three hospital systems in September filed a lawsuit to force implementation of this rule in order to “shine needed light on drug pricing and to hold price-gouging drug companies accountable.”
 

Related News Articles

Headline
The AHA, joined by several other national groups representing 340B hospitals, Aug. 8 urged the Health Resources and Services Administration to extend the…
Headline
The AHA today filed an amicus brief in the U.S. Court of Appeals for the D.C. Circuit, defending the Department of Health and Human Services’ decision to…
Headline
The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the…
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug…
Headline
Rep. Doris Matsui, D-Calif., and Sen. Peter Welch, D-Vt., today introduced the 340B Patients Act, AHA-supported legislation that would codify 340B providers'…
Headline
The AHA July 16 filed an amicus brief in the U.S. District Court for the District of Colorado in defense of the state’s 340B contract pharmacy law prohibiting…